A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice

Injectable Excipients as Novel Influenza Vaccine Adjuvants

(2019) Huapeng Feng et al.   Frontiers in Microbiology

Current and future influenza vaccines

(2019) Seiya Yamayoshi et al.   NATURE MEDICINE

Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture

(2018) Daniela S. Rajão et al.   Frontiers in Microbiology

Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018

(2018) Brendan Flannery et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

The Effectiveness of Influenza Vaccination in Different Groups

(2016) Angela Domínguez et al.   Expert Review of Vaccines

Least-Squares Means: TheRPackagelsmeans

(2016) Russell V. Lenth   Journal of Statistical Software

Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs

(2016) Varun Dwivedi et al.   VETERINARY MICROBIOLOGY

OASIS 2: online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research

(2016) Seong Kyu Han et al.   Oncotarget

α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant

(2016) Bianca L. Artiaga et al.   Scientific Reports

Influenza Vaccines: Challenges and Solutions

(2015) Katherine Houser et al.   Cell Host & Microbe

Fitting Linear Mixed-Effects Models Usinglme4

(2015) Douglas Bates et al.   Journal of Statistical Software

Suboptimal Effectiveness of the 2011–2012 Seasonal Influenza Vaccine in Adult Korean Populations

(2015) Won Suk Choi et al.   PLoS One

Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus

(2014) Jung-Tung Hung et al.   ANTIVIRAL RESEARCH

Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii

(2014) Gang Lu et al.   BMC INFECTIOUS DISEASES

Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine

(2014) Ryuta Uraki et al.   VACCINE

Toward a Universal Influenza Virus Vaccine: Prospects and Challenges

(2013) Natalie Pica et al.   Annual Review of Medicine

A Glycolipid Adjuvant, 7DW8-5, Enhances CD8+ T Cell Responses Induced by an Adenovirus-Vectored Malaria Vaccine in Non-Human Primates

(2013) Neal N. Padte et al.   PLoS One

Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer

(2013) Y.-L. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells

(2012) Enrico Girardi et al.   IMMUNOLOGICAL REVIEWS

Adjuvants in influenza vaccines

(2012) Kohhei Tetsutani et al.   VACCINE

Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly

(2012) Roberto Gasparini et al.   Human Vaccines & Immunotherapeutics

Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of  -GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells

(2011) A. J. Nicol et al.   CLINICAL CANCER RESEARCH

Neonatal immunization: where do we stand?

(2011) Nicholas Wood et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine

(2011) D. S. Miller et al.   JOURNAL OF GENERAL VIROLOGY

Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice

(2011) Saori Sakabe et al.   VIRUS RESEARCH

Vaccine adjuvants – Current status and prospects on controlled release adjuvancity

(2011) S.M. Sivakumar et al.   SAUDI PHARMACEUTICAL JOURNAL

New adjuvants for human vaccines

(2010) M Lamine Mbow et al.   CURRENT OPINION IN IMMUNOLOGY

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant

(2010) X. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells

(2010) Daejin Kim et al.   VACCINE

An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine

(2010) Yoon-Sook Lee et al.   VACCINE

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity

(2009) C. Guillonneau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine

(2009) Sarah A. Kopecky-Bromberg et al.   VACCINE

Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

(2008) H Kamijuku et al.   Mucosal Immunology

α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

(2008) Youn Seok Choi et al.   VACCINE

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide

(2008) Yaoxing Huang et al.   VACCINE